Anne M Fagan Niven, PhD

Professor of Neurology

Phone314-362-3453

Fax314-362-2244

Emailfagana@neuro.wustl.edu

Related Links

Publications

  • Kauwe JSK, Cruchaga C, Bertelsen S, Mayo K, Latu W, Nowotny P, Hinrichs AL, Fagan AM, Holtzman DM, ADNI and Goate AM. Validating predicted biological effects of Alzheimer’s disease associated SNPs using CSF biomarker levels. J Alzheimer Dis, 2010, in press.
  • Ances BM, Christensen JJ, Teshome M, Taylor J, Xiong C, Aldea P, Fagan AM, Holtzman DM, Morris JC, Mintun MA, Clifford DB. Cognitively unimpaired HIV+ participants do not have increased 11C-PiB: A case control study. Neurology, 2010, in press. [PMC Journal – In process]
  • Fagan AM and Holtzman DM. CSF biomarkers of Alzheimer’s disease. Future Med, 2010, 4:51-63. [PMC Journal – In process]
  • Hinrichs AL, Mintun MA, Head D, Fagan AM, Holtzman DM, Morris JC, Goate AM. Cortical binding of Pittsburgh Compound B, an endophenotype for genetic studies of Alzheimer’s disease. Biol. Psychiatry, 2009, in press. NIHMSID: 171962
  • Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med, 2009, 1:371-80. PMCID: PMC2806678
  • Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease, Nature, 2009, 461:916-22 PMCID: PMC2810658
  • Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. PIB imaging predicts progression from cognitively normal to symptomatic Alzheimer’s disease, Arch Neurol, 2009, 66:1469-75. PMCID: PMC2798814
  • Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Taylor-Reinwald L, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease, Arch Neurol, 2009, 66:1557-62. PMCID: PMC2796200
  • Morris JC, Roe CM, Xiong C, Fagan AM, Goate Am, Holtzman DM, Mintun MA. APOE predicts Aβ but not tau Alzheimer’s pathology in cognitively normal aging, Ann Neurol, 2010, 67:122-31. PMCID: PMC2830375
  • Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Taylor-Reinwald L, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease, Arch Neurol, 2009, 66:1557-62. PMCID: PMC2796200
  • Morris JC, Roe CM, Xiong C, Fagan AM, Goate Am, Holtzman DM, Mintun MA. APOE predicts Aβ but not tau Alzheimer’s pathology in cognitively normal aging, Ann Neurol, 2010, 67:122-31. PMCID: PMC2830375
  • Duchek JM, Balota DA, Tse CS, Holtzman DM, Fagan AM, Goate AM. The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer’s disease. Neuropsychology, 2009, 23:746-58. PMCID: PMC2779520
  • Clifford DB, Fagan AM, Holtzman DM, Morris, JC, Teshome M, Shah AR, Kauwe JSK. CSF biomarkers of Alzheimer’s Disease in HIV associated neurological disease. Neurology, 2009, 73:1982-87. PMCID: PMC2790234
  • Britschgi M, Olin CO, Johns HT, Takeda-Uchimura Y, LeMieux M, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DG, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso J., and Wyss-Coray T. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. PNAS, 2009, 106:12145-50. PMCID: PMC2715538
  • Snider BJ, Fagan AM, Roe CM, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer’s type. Arch Neurol, 2009, 66:638-45. PMCID: PMC2759394
  • Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer’s disease. Neurobiol Dis., 2009, 35:128-40. PMCID: PMC2747727
  • Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM. Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics. 2009,10:13-7. PMCID: PMC2726757
  • Okereke OI, Xia W, Irizarry MC, Sun X, Qiu WQ, Fagan AM, Mehta PD, Hyman BT, Selkoe DJ, Grodstein F. Performance characteristics of plasma amyloid-beta 40 and 42 assays. J Alzheimers Dis., 2009,16:277-85. PMCID: PMC2737811
  • Fagan AM, Head, D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009, 65:176-183. PMCID: PMC2763631
  • Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, Nowotny P, Galimberti D, Scarpini E, Morris JC, Fagan AM, Holtzman DM, Goate AM. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. PNAS, 2008 105:8050-4. PMCID: PMC2430357
  • Lemere CA, Oh J, Stanish HA, Peng Y, Pepivani I, Fagan AM, Yamaguchi H, Westmoreland SV, Mansfield KG. Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: A model of early Alzheimer’s disease? Rejuv. Res., 2008, 11: 321-332. Accepted prior to April 7, 2008.
  • Hu Y, Hosseini A, Kauwe JSK, Gross J, Cairns NJ, Goate AM, Fagan AM, Townsend RR, Holtzman DM Identification and validation of novel CSF biomarkers for early stages of Alzheimer’s disease. Proteomics – Clin. Appl., 2007, 1:1373-1384.
  • Wahrle SE, Shah AR, Fagan AM, Smemo S, Kauwe JSK, Grupe A, Hinrichs A, Mayo K, Jiang H, Thal LJ, Goate AM, Holtzman DM. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol. Neurodegen., 2007, Apr 12;2:7.
  • Kauwe JSK, Jacquart S, Chakraverty S, Wang J, Mayo K, Mintun M, Fagan AM, Holtzman DM, Morris JC, Goate AM. Use of cerebrospinal fluid amyloid-β levels as an endophenotype identifies a PSEN1 mutation causing Alzheimer’s disease in a late-onset family. Ann. Neurol., 2007, 61(5):446-53.
  • Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, and Morris JC. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia, Am. J. Psychiatry, 2006, 163:2164-9. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM Cerebrospinal fluid tau/-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults, Arch. Neurol., 2007, 64:343-49.
  • Fagan AM, Csernansky CA, Morris JC, Holtzman DM. The search for antecedent biomarkers of Alzheimer’s disease, J. Alzheimer’s Dis., 2005, 8:347-358.
  • Fagan AM, Mintun MA, Mach RH, Lee S-Y, Dence CS, Shah AR, LaRossa G, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and CSF A42 in humans, Ann. Neurol., 2006, 59:512-519.
  • Hu Y, Townsend R, Fagan AM, Holtzman DM. Comparative proteomics analysis of intra- and inter-individual variation in human cerebrospinal fluid, Mol. Cell. Proteomics, 2005, 4:2000-2009.
  • Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM. P-glycoprotein deficiency at the blood-brain barrier increases amyloid- deposition in an Alzheimer’s disease mouse model, J. Clin. Invest., 2005, 115:3285-3290.
  • Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos RB, O’Dell MA, Fagan AM, Lashuel HA, Walz T, Asai K, Holtzman DM. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta, Neurobiol. Dis., 2005, 19:66-76.

In 1995, Anne was recruited to Washington University School of Medicine by Dr. David Holtzman, a long-time colleague, to gain training in Alzheimer’s Disease (AD), and subsequently received her faculty appointment in the Department of Neurology in 1997.

In her post-doctoral and early faculty yeyars Anne investigated the mechanism(s) by which the E4 isoform of apolipoprotein E (apoE) is a risk factor for AD. Her multidisciplinary approach, utilizing biochemical and cell biological experiments coupled with analysis of in vivo transgenic mouse models of AD, was instrumental in defining an important role for apoE in the metabolism of amyloid- (A), the protein that accumulates and forms plaques in the AD brain. Over the past twelve years, her interests have expanded into the AD biomarker field, with publications describing the utility of various CSF measures as diagnostic and prognostic biomarkers of preclinical and early stage AD.